Drugs / Doripenem

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Withdrawn EU (EMA) Doribax 2014-07-31 europa.eu
Approved EU (EMA) Doribax 2008-07-25 europa.eu
Approved US (FDA) DORIBAX 2007-10-12 fda.gov

Trials 22 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01366651 Mar → May 2012 meningitis Janssen Research & Development, LLC Terminated No outcome recorded
Phase 1 NCT01381848 Oct 2009 → Apr 2012 bacterial infectious disease Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT00925392 Jun 2009 → Jan 2010 Keith A. Rodvold Completed No outcome recorded
Phase 22 trials
Phase 2 NCT00515034 Oct 2007 → Nov 2008 abscess, bacterial pneumonia Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 2 NCT00502801 Aug 2007 → Nov 2008 bacterial pneumonia, nosocomial infection PriCara, Unit of Ortho-McNeil, Inc. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02134106 Jan → Oct 2015 bacterial infectious disease, nosocomial infection Tan Tock Seng Hospital Withdrawn No outcome recorded
Phase 310 trials
Phase 3 NCT01110408 Dec 2010 → Jun 2013 urinary tract infection Janssen Research & Development, LLC Terminated No outcome recorded
Phase 3 NCT01110421 Dec 2010 → Mar 2012 bacterial pneumonia, nosocomial infection Janssen Research & Development, LLC Terminated No outcome recorded
Phase 3 NCT01110382 Dec 2010 → Sep 2013 abscess, appendicitis, ileus, intestinal perforation +1 Janssen Research & Development, LLC Terminated No outcome recorded
Phase 3 NCT00589693 Apr 2008 → Jun 2011 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Terminated No outcome recorded
Phase 3 NCT00211016 Aug 2004 → Oct 2006 pneumonia Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 3 NCT00211003 May 2004 → Oct 2006 pneumonia Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 3 NCT00229060 Mar 2004 → Mar 2006 appendicitis, bacterial infectious disease, cholecystitis, pancreatitis +1 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 3 NCT00210938 Mar 2004 → Jan 2006 appendicitis, bacterial infectious disease, cholecystitis, pancreatitis +1 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 3 NCT00210990 Mar 2004 → Apr 2006 pyelonephritis Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 3 NCT00229021 Dec 2003 → Mar 2006 pyelonephritis Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 45 trials
Phase 4 NCT01467648 Oct 2010 → Oct 2011 Sutep Jaruratanasirikul Completed No outcome recorded
Phase 4 NCT01311141 Aug 2010 → Mar 2011 Medical University of Vienna Completed No outcome recorded
Phase 4 NCT01027897 Apr 2010 → Dec 2011 infectious disease with sepsis Emory University Completed No outcome recorded
Phase 4 NCT00986102 Jul 2009 → Sep 2011 pneumonia, urinary tract infection Janssen Research & Development, LLC Completed No outcome recorded
Phase 4 NCT00965848 Jun 2009 → Jul 2010 bacterial infectious disease, nosocomial infection, urinary tract infection Janssen-Cilag Ltd.,Thailand Completed No outcome recorded
Phase not applicable1 trial
NCT01517815 Feb 2012 → Jun 2013 infectious disease with sepsis University Hospital, Montpellier Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01281462 Comparator Dec 2010 → Mar 2012 urinary tract infection Forest Laboratories Completed No outcome recorded
Phase 32 trials
Phase 3 NCT01599806 Comparator Oct 2012 → Aug 2014 acute pyelonephritis Pfizer Completed No outcome recorded
Phase 3 NCT01595438 Comparator Oct 2012 → Aug 2014 acute pyelonephritis Pfizer Completed No outcome recorded
Phase 41 trial
Phase 4 NCT01401010 Comparator Aug 2010 → Feb 2012 neutropenia Gary E. Stein, Pharm.D. Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 28 sources stand behind the page.

FieldValueCited text
Known as Doripenem Doripenem was evaluated in adults with complicated urinary tract infections and pyelonephritis in two phase 3 studies.” PMID 21303745 Dec 2010
25

NCT01281462

NCT01595438

NCT01027897

NCT00986102

NCT00925392

NCT01599806

NCT01467648

NCT00589693

NCT02134106

NCT00965848

NCT00211016

NCT01401010

NCT01366651

NCT00515034

NCT01311141

NCT00229060

NCT01110421

NCT01110408

NCT01110382

NCT00502801

NCT00210938

NCT00210990

NCT00211003

NCT01381848

NCT01517815

Known as [14C]-DORIPENEM ChEMBL registry synonym — accepted as the source's own label CHEMBL491571
Known as Doribax ChEMBL registry synonym — accepted as the source's own label CHEMBL491571
Known as Doripenem (Doribax) Doripenem (Doribax)NCT01467648
Known as Doripenem hydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL491571
Known as DORIPENEM MONOHYDRATE ChEMBL registry synonym — accepted as the source's own label CHEMBL491571
Known as Dripenem hydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL491571
Known as Finibax ChEMBL registry synonym — accepted as the source's own label CHEMBL491571
Known as S-4661 ChEMBL registry synonym — accepted as the source's own label CHEMBL491571
Modality Small molecule “Doripenem is a new carbapenem, recently approved in the US for the treatment of adults with complicated urinary tract infections (cUTI) or complicated intra-abdominal infections (cIAI)” PMID 19670912 2009
Route Intravenous intravenous doripenem versus a comparator antibiotic” NCT00210938